Pharmaceuticals
Developers of branded and generic drugs. Value creation rests on R&D pipelines, patent lifecycles, regulatory approvals and pricing power versus payers.
| Company | Last Price | Price Change | Market Cap | ||
|---|---|---|---|---|---|
|
|
|
Eli Lilly and Co
LLY
|
$1 347.11 |
-0.3%
|
$1.3T |
|
|
|
Johnson & Johnson
JNJ
|
$270.47 |
+1.2%
|
$651.1B |
|
|
|
Merck & Co Inc
MRK
|
$133.72 |
+0.7%
|
$329.9B |
|
|
|
Novartis AG
NOVN
|
CHf127.76 |
+0.4%
|
$289.2B |
|
|
|
AstraZeneca PLC
AZN
|
13 412 |
+0.8%
|
$272.1B |
|
|
|
Novo Nordisk A/S
NOVO B
|
kr264.5 |
-0.2%
|
$171.3B |
|
|
|
Pfizer Inc
PFE
|
$27.4 |
-0.5%
|
$156.2B |
|
|
|
Bristol-Myers Squibb Co
BMY
|
$58.8 |
+0.8%
|
$120.2B |
|
|
|
Sanofi SA
SAN
|
€84.92 |
+1.3%
|
$112.6B |